Imbaba, Egypt

The Theodor Bilharz Research Institute is located in Giza, Egypt.Theodor Bilharz was a German scientist who discovered, in autopsy material at Kasr El Aini Hospital, the causative agent of haematuria: Schistosoma worm, during his work in Egypt in 1851. The bilhariziasis disease was named after him.The idea of initiating the institute was elaborated in 1960 via high council of science, owing to the magnitude of schistosomiasis problem in Egypt specially in the rural population and its impact on the socioeconomic life. The objective of the institute was to tackle this diseases from all its aspects : control, diagnosis and management.In 1960, Ahmed Hafez Mousa,the real originator of the institute and one of the world's pioneers in the field of Tropical Medicine was charged to fulfill this idea. He appointed the Tropical Medicine Department at Kasr El Aini, Faculty of Medicine a preliminary location for a small nuclear start of this project. This was followed by the establishment of a "Laboratory for Schisosomiasis Research" in the chemistry building of the National Research Center.In April 1962, the foundation stone of the institute was implemented at Warak El Hader's village in Giza governorate. Meanwhile the building of the institute was constructed by Egyptian Government, the laboratories and hospital were equipped through an agreement between the governments of Federal Republic of Germany and Egypt in 1964.In 1977 The institute construction was accomplished, and opened for public, headed by Ali Zain El-Abdeen. in 1979. Ahmad Algarim became the head of the institute, and until 1987. In 1987, Aly Zain Al- Abdeen headed the institute and till his retirement in 1994.In 1977, the institute was officially affiliated to the Ministry of Scientific Research By June 1978 the TBRI's laboratories and out-patients clinic were inaugurated. The attached hospital was completed in December 1981, and the official opening was in 1983 according the Presidential Decree No. 58. Wikipedia.


Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CSA-SA | Phase: INCO.2010-6.2 | Award Amount: 561.49K | Year: 2010

The THEBERA project aims at strengthening capacities of the Theodor Bilharz Research Institute (TBRI) in Egypt while realizing it as an international excellence and reference centre for liver diseases and Hepatic surgery excellence by defining liver research priorities to respond to socio-economic needs, facilitating participation in European liver research initiatives and inclusion in Euro-Mediterranean Research and Innovation Area. The specific objectives of THEBERA project are: - TBRIs Cooperation Capacities Reinforcement - Liver-Related Research Results Dissemination - Internationalization and Coordination between Research and Business Sectors - Enhancement of EU-Egypt S&T Partnerships in Liver Research - Capacity Building for Cooperation - Developing THEBERA Centres Strategy The project thus addresses current Work Programme for International Cooperation to reinforce the cooperation capacities of research centres located in the ENP countries and contributes to the European international co-operation in science and technology strategy implementation, while strengthening the international dimension of the ERA and improving the framework conditions for international S&T cooperation. The main impact of THEBERA will be increased capacities of the TBRI and the structuring and enhancement of the existing EU-EG support system in the domain of Liver S&T cooperation in a threefold manner: (i) by supporting the participation of Egypt in the FP7 in liver research area, (ii) combining all relevant support schemes, and (iii) facilitating both the uptake of common identified liver research areas and the monitoring of the performance and impacts of this cooperation. The THEBERA consortium brings together 4 Egyptian and EU organisations representing a well-defined mix of competencies and expertise.


Bouchard S.,Erasme Hospital | Ibrahim M.,Theodor Bilharz Research Institute | Van Gossum A.,Erasme Hospital
World Journal of Gastroenterology | Year: 2014

Video capsule endoscopy (VCE) was launched in 2000 and has revolutionized direct endoscopic imaging of the gut. VCE is now a first-line procedure for exploring the small bowel in cases of obscure digestive bleeding and is also indicated in some patients with Crohn's disease, celiac disease, and polyposis syndrome. A video capsule has also been designed for visualizing the esophagus in order to detect Barrett's esophagus or esophageal varices. Different capsules are now available and differ with regard to dimensions, image acquisition rate, battery life, field of view, and possible optical enhancements. More recently, the use of VCE has been extended to exploring the colon. Within the last 5 years, tremendous developments have been made toward increasing the capabilities of the colon capsule. Although colon capsule cannot be proposed as a first-line colorectal cancer screening procedure, colon capsule may be used in patients with incomplete colonoscopy or in patients who are unwilling to undergo colonoscopy. In the near future, new technological developments will improve the diagnostic yield of VCE and broaden its therapeutic capabilities. © 2014 Baishideng Publishing Group Inc. All rights reserved.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.4-2 | Award Amount: 7.80M | Year: 2014

This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery platform, PDE4NPD, that combines phenotypic screening with efficient target-centric drug discovery, including target validation, various strategies for compound screening, PDE hit and lead optimization, safety and toxicology assessments and evaluation of anti-parasitic activity. The platform will make use of the target class expertise that the participating SMEs have gained when developing drugs for human and parasite PDEs, while all public partners offer proven experience in the field of NPD. The SMEs will adopt and progress existing PDE inhibitors that are in different stages of the drug discovery pipeline (i.e., target validation, hit and lead optimization). The current portfolio of inhibitors have clinical potential for treating sleeping sickness, Chagas disease and leishmaniasis. Finding novel hits and leads for the PDEs that are associated with helminth diseases is also foreseen. The platform is open for targeting other NPD, and a broad panel of phenotypic screens (including malaria) is available to test PDE inhibitors. The phenotypic screening is performed by world-renowned groups, including two institutes in endemic countries. By capturing human and parasite PDE-related data in annotated chemogenomics databases, PDE-4-NPD will achieve the knowledge accumulation that is typical for target-centric approaches, thereby making the NPD drug development more efficient and enabling the SMEs to take advantage of the molecular understanding that is key for developing new medicines. The PDE4NPD platform constitutes an ideal basis for creating fruitful collaborations with both public and private partners word-wide.


Van Gossum A.,Free University of Brussels | Ibrahim M.,Theodor Bilharz Research Institute
Gastroenterology Clinics of North America | Year: 2010

Video capsule endoscopy (VCE) that was launched 10 years ago has become a first-line procedure for examining the small bowel, especially in the case of obscure gastrointestinal bleeding. Other major indications include Crohn disease (CD), celiac disease, and intestinal polyposis syndrome. In the case of small bowel diseases, the use of VCE must be integrated in a global diagnostic and therapeutic approach. More recently, wireless endoscopy has been adapted for examining the colon, opening up larger perspectives for colorectal cancer screening or colon examination. Technologic modifications of the second-generation colon capsule increase the sensitivity of this method for detecting polyps. Other new developments, including remote magnetic manipulation, power management, drug delivery capsule, microbiopsy capsule, and adaptation of technologies such as chromoendoscopy, are sure to enhance the capabilities of wireless endoscopy in gastrointestinal disorders. © 2010 Elsevier Inc.


Abdallah E.,Theodor Bilharz Research Institute
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia | Year: 2013

Acute kidney injury (AKI) is a common and serious condition in both the inpatient and outpatient settings, and its diagnosis depends on serum creatinine measurements. Unfortunately, creatinine is a delayed and unreliable indicator of AKI. The lack of early biomarkers has limited our ability to translate promising experimental therapies to human AKI. Fortunately, understanding the early stress response of the kidney to acute injuries has realized a number of potential biomarkers. For example, neutrophil gelatinase-associated lipocalin is emerging as an excellent stand alone troponin-like biomarker in the plasma and urine for predicting and monitoring clinical trials and in the prognosis of AKI. In recent years, a number of new biomarkers of AKI with more favorable test characteristics than creatinine have been identified and studied in a variety of experimental and clinical settings. This review will consider the most well-established biomarkers of AKI.


Abdallah E.,Theodor Bilharz Research Institute
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia | Year: 2013

The kidneys are affected in almost all patients with amyloid A in secondary amyloidosis (AA) amyloidosis but less frequently in immunoglobulin light chains in primary systemic amyloidosis (AL) amyloidosis. In this study, we present the incidence, etiology, clinical manifestations, biochemical features and clinical course of renal amyloidosis. We conducted a retrospective study on a group of 40 cases with renal biopsy-proven amyloidosis. They constituted 2.5% of the total cases of renal biopsies performed in the Theodor Bilharz Research Institute, Cairo, Egypt, during the period from February 2003 to May 2009. The mean age (30 males, ten females) was 36.51 ± 10.32 years. Thirty-two of the cases had secondary AA amyloidosis and eight cases had primary AL amyloidosis. The causes of secondary amyloidosis were as follows: 12 (30%) familial Mediterranean fever (FMF), eight (20%) pulmonary tuberculosis, four (10%) chronic osteomyelitis, four (10%) bronchiectasis, three (7%) rheumatoid arthritis and one (2%) rheumatic heart disease. The eight cases of primary AL amyloidosis comprised of five cases that were associated with myloma (13%) and three (8%) cases that were idiopathic. Among the 23 patients with AA amyloidosis, after six months of treatment with colchicine, the proteinuria improved, serum albumin level increased and edema disappeared in 13 patients. In four cases of AA amyloidosis who were clinically and biochemically normal after cholchicine therapy, a second renal biopsy disclosed decreased amyloid deposition compared with the first biopsy. In the three renal transplanted patients who had amyloidosis secondary to FMF and were treated with colchicines, AA amyloidosis did not recur in the transplanted kidney. It might be possible that in AL amyloidosis, treatment with methotrexate, melphalan and prednisolone may improve survival. The incidence of renal amyloidosis is increasing and colchicine can be used in secondary amyloidosis as it may have an effect on reducing the production of the amyloid precursor proteins and in reducing proteinuria.


Honeycutt J.,Stanford University | Hammam O.,Theodor Bilharz Research Institute | Fu C.-L.,Stanford University | Hsieh M.H.,Stanford University
Trends in Parasitology | Year: 2014

Urogenital schistosomiasis, infection with Schistosoma haematobium, is linked to increased risk for the development of bladder cancer, but the importance of various mechanisms responsible for this association remains unclear, in part, owing to lack of sufficient and appropriate animal models. New advances in the study of this parasite, bladder regenerative processes, and human schistosomal bladder cancers may shed new light on the complex biological processes that connect S. haematobium infection to bladder carcinogenesis. © 2014 Elsevier Ltd.


El-Lakkany N.M.,Theodor Bilharz Research Institute | Seif El-Din S.H.,Theodor Bilharz Research Institute
Parasitology Research | Year: 2013

Among the potential alternatives to praziquantel, interestingly, the antimalarial artemether (Art) also exhibits antischistosomal properties. Previous in vitro studies suggested that Art interacts with haemin and together produce a lethal agent against schistosomes. This study investigates the in vivo effect of Art plus haemin on juvenile and adult Schistosoma mansoni worms and on their antioxidant enzymes. Infected mice were allocated into two batches each in four groups (I-IV): (I) untreated control; (II) injected with haemin (ip, 100 mg/kg/day) on days 26, 27, and 28 post-infection (PI) for juvenile stage and on days 47, 48, and 49 PI for adult stage; (III) treated with a single oral dose of Art (300 mg/kg) either after 28 or 49 days PI, respectively; and (IV) received both haemin, as group (II) and Art as group (III). Half of mice for each batch were killed 72 h; meanwhile, the remaining half was killed 3 weeks after Art administration. Parasitological criteria of cure and worms' antioxidant enzymes were assessed. Glutathione S-transferase (GST), glutathione peroxidase (GPx), glutathione reductase (GR), and superoxide dismutase (SOD) activities were lower in juvenile worms than adult ones and in females than males. Haemin plus Art at the juvenile and adult stages produced significant inhibition in worms' GST, GPx, and SOD activities 72 h after Art treatment, compared with Art-treated group, with enhanced killing of females (96.98 and 91.47 % versus 87.04 and 72.97 %, respectively) and total worms (91 and 83.39 % versus 75 and 59.01 %, respectively) 3 weeks posttreatment. In conclusion, Art plus haemin has a higher harmful effect on juvenile and adult schistosomes and antioxidant capacity than Art alone. This gives new insights into the importance of haemin in the antischistosomal properties of artemether. © 2013 Springer-Verlag Berlin Heidelberg.


Hassan A.M.,Theodor Bilharz Research Institute
Journal of the Egyptian Society of Parasitology | Year: 2012

This prospective study was conducted to investigate the efficacy of single-dose Ceftazidime as a prophylactic antibiotic to prevent surgical site infections in low-risk patients undergoing LC. Two hundred patients included in the study were randomly divided into two groups (100 each): G1: patients received intravenous Ceftazidime within 60 minutes prior to surgery and G2: received intravenous placebo (10 ml isotonic sodium chloride 0.9% solution). All patients were invited for examination 10, 20 and 30 days post-operatively and any post-operative complications were recorded and managed. Preoperatively; there was no significant differences existed between the 2 groups regarding sex, age; body mass index and ASA score. Also, the duration of LC surgery, incidence of intra-operative gallbladder perforations and spill of bile or stones, incidents of intra-operative bleeding from either cystic artery or gall bladder liver bed and mean postoperative hospital stay were found not significantly different between the 2 groups. Post operatively there was no statistical difference regarding the surgical site infection between the two groups.


Ali M.Z.,Theodor Bilharz Research Institute
Journal of the Egyptian Society of Parasitology | Year: 2011

The efficacy, safety and ease of insertion of LMA Supreme and the i-gel in adult cases undergoing elective surgical procedures requiring general anesthesia with controlled mechanical ventilation. This study included 60 ASA physical status I-II adult patients of both sexes scheduled for elective surgical procedures under general anesthesia. Patients were randomly allocated into one of two groups; LMA-S GI (n=30) and i-gel GII (n=30). A size 4 LMA Supreme and a size 4 i-gel were used with standard monitoring. Number of insertion attempts, ease of insertion, presence of gastric insufflation, laryngeal leak, leak pressure, ease of gastric tube insertion, ventilatory parameters, complications as well as hemodynamic variables was recorded. The results showed no clinically significant changes of heart rate, MAP, SpO2 or P(ET)CO2 in GI & GII. The i-gel showed higher frequency of ease of insertion (p=0.048) and gastric tube (p< 0.001). First attempt of insertion was successful in 60% of LMA-S GI and 73.3% of the i-gel GII (p=0.460) without failures in both groups. Leak pressure was significantly higher in the i-gel (25.5 +/- 4.8 cm H2O) compared to the LMA-S (21.1 +/- 7.6 cm H2O) (p=0.010) while both peak and plateau pressures were significantly lower in i-gel GI (19.35 +/- 2.25 cm H2O & 17.75 +/- 2.07 cm H2O) compared to LMA-S GII (30.05 +/- 3.82 cm H2O & 28.80 +/- 3.99cm H2O) (p<0.001) respectively. There was no significant difference between both groups in the frequency of complications encountered during insertion or recovery.

Loading Theodor Bilharz Research Institute collaborators
Loading Theodor Bilharz Research Institute collaborators